In this article we will discuss Anlotinib Tolerability (2). So, let’s get started.
All adverse events (AEs) appeared to be manageable in
the phase I trial. The most common AEs with over 30%
incidence were hand-foot skin reaction (53%), hyperten-
sion (34%), proteinuria (67%), triglyceride elevation
(62%), total cholesterol elevation (62%), hypothyroidism
(57%), alanine aminotransferase (ALT) elevation (48%),
aspartate transaminase (AST) elevation (43%), total bili-
rubin elevation (38%), serum amylase (43%), myocardial
enzymes abnormal (38%), leucopenia (33%), and neutro-
penia (33%).